Received Oct 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 3T74X | — |
female patient got a third dose of SHINGRIX in the same day; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 57-year-old female patient who received Herpes zoster (Shingrix) (batch number 3T74X, expiry date 28-APR-2027) for prophylaxis. Previously administered products included Shingrix (received 1st dose on an unknown date) and Shingrix (received 2nd dose in AUG-2023). On 06-OCT-2025, the patient received the 3rd dose of Shingrix. On 06-OCT-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: female patient got a third dose of SHINGRIX in the same day). The outcome of the extra dose administered was not applicable. Additional Information: GSK receipt date: 06-OCT-2025 The patient received 3rd dose of Shingrix, which led to extra dose administered. The patient got the full vaccine series back in August 2023 and the pharmacist wanted to know if there were some safety concerns to take care of for the patient.